Last reviewed · How we verify
NCT05595408
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
trial testing Adjuvant chemotherapy in Muscle Invasive Upper Tract Urothelial Carcinoma in 84 participants. Currently enrolling.
3 November 2025
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 84 |
| Start date | 1 February 2022 |
| Primary completion | 3 November 2025 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Adjuvant chemotherapy — full drug profile →
- adjuvant immunotherapy — full drug profile →
Conditions studied
- Muscle Invasive Upper Tract Urothelial Carcinoma — all drugs for Muscle Invasive Upper Tract Urothelial Carcinoma →
Sponsor
RenJi Hospital
Who can join
18 and older, any sex, with Muscle Invasive Upper Tract Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma.
Bhalla S, Passarelli R, Biswas A, De S, et al · · 2024 · cited 10× · PMID 38610824 · DOI 10.3390/jcm13072057 -
Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.
Jaime-Casas S, Tripathi A, Pal SK, Yip W. · · 2024 · cited 6× · PMID 39379745 · DOI 10.1007/s11934-024-01245-1 -
Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers.
Kapriniotis K, Loufopoulos I, Sharif MU, Manolitsis I, et al · · 2026 · PMID 42042587 · DOI 10.3390/jpm16040220
Verify or expand the search:
- PubMed search for NCT05595408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Adjuvant chemotherapy
Trials testing the same drug.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07413146 — Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Lab · NA · not yet recruiting
- NCT06476119 — OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infi · recruiting
- NCT06520683 — Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer · Phase 3 · recruiting
- NCT06427447 — Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) · Phase 3 · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05595408 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05595408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing